secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovAccess Global Inc. (—)
CIK:        0001039466
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001185185-24-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 5.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovAccess Global secures $10.7M financing from Sumner Global; Sumner to gain majority control
--------------------------------------------------------------------------------

- Sumner will purchase 33.0M shares at $0.11/share ($3.63M) and lend $7.05M via convertible notes at 10% interest.
- Convertible notes due in 5 years, convertible at $0.11/share; first tranche of $3.05M due Feb 15, 2024, second $4M due Mar 15, 2024.
- CEO's affiliate converts 600 Series B preferred shares into 6M common shares upon closing, eliminating all preferred stock.
- Post-transaction Sumner will hold a majority of outstanding common shares, gaining ability to control shareholder votes.
- Proceeds to fund operations, repay debt, and advance brain tumor immunotherapy (TLR-AD1) pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1039466/000118518524000010/0001185185-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1039466/000118518524000010/novaccess20231031_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer